Deregulating iron-erythropoiesis regulation: transferrin receptor 2 as potential target for treating anemia in CKD
Mark J Koury1, Volker H Haase2
1Division of Hematology/Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA; Medical Service, Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, Tennessee, USA.
Abstract:
Both insufficient kidney production of erythropoietin and inflammation-mediated reduction of transferrin-bound iron are major factors in anemia of chronic kidney disease. Improved therapies for anemia in chronic kidney disease may involve modifying regulators of erythropoiesis and iron availability. Olivari et al. show in a mouse model of chronic kidney disease that transferrin receptor 2 in hepatocytes, where it is required for hepcidin production, and in erythroid cells, where it downregulates erythropoietin receptor activity, is a potential therapeutic target.
More Related Videos
06:40Mouse Fetal Liver Culture System to Dissect Target Gene Functions at the Early and Late Stages of Terminal Erythropoiesis
Published on: September 9, 2014
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Related Concept Videos
The Early Endosome: Endocytosis of Transferrin
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Kidney Transplant I: Introduction
